Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.
haemodialysis
hyperphosphataemia
mineral and bone disease
nicotinamide
randomized controlled trial
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
31 03 2023
31 03 2023
Historique:
received:
28
01
2022
medline:
4
4
2023
pubmed:
26
6
2022
entrez:
25
6
2022
Statut:
ppublish
Résumé
We previously reported that modified-release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here we report outcomes after 52 weeks of treatment. NOPHOS was a phase 3, international, randomized, controlled, double-blind trial with a parallel group design. NAMR (250-1500 mg/day) was investigated in comparison to placebo as an add-on therapy to an individual therapy with approved phosphate binders. In the intention-to-treat population (NAMR: n = 539; placebo: n = 183), serum phosphate was significantly lower in the NAMR group compared with the placebo group at week 24 (5.40 ± 1.55 versus 5.79 ± 1.37 mg/dl, P < .001) with a mean difference of -0.39 mg/dl [95% confidence interval (CI) -0.66 to -0.13], but was comparable between the groups at week 52 [mean difference -0.08 (95% CI -0.36-0.20)]. In the completer population (n = 358), statistical significance in favour of NAMR was reached at weeks 24 and 52. The treatment effect was reduced in patients with high baseline serum intact parathyroid hormone (iPTH) compared with patients with low baseline serum iPTH. Compliant patients in the NAMR group had a more pronounced and sustained reduction in serum phosphate than non-compliant patients. NAMR treatment was associated with a significantly increased risk of thrombocytopenia, pruritus, anaemia, and diarrhoea. Herpes zoster occurred exclusively in patients randomized to NAMR. NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Non-compliance may have contributed to reduced long-term efficacy. Several newly identified safety signals warrant further evaluation.
Sections du résumé
BACKGROUND
We previously reported that modified-release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here we report outcomes after 52 weeks of treatment.
METHODS
NOPHOS was a phase 3, international, randomized, controlled, double-blind trial with a parallel group design. NAMR (250-1500 mg/day) was investigated in comparison to placebo as an add-on therapy to an individual therapy with approved phosphate binders.
RESULTS
In the intention-to-treat population (NAMR: n = 539; placebo: n = 183), serum phosphate was significantly lower in the NAMR group compared with the placebo group at week 24 (5.40 ± 1.55 versus 5.79 ± 1.37 mg/dl, P < .001) with a mean difference of -0.39 mg/dl [95% confidence interval (CI) -0.66 to -0.13], but was comparable between the groups at week 52 [mean difference -0.08 (95% CI -0.36-0.20)]. In the completer population (n = 358), statistical significance in favour of NAMR was reached at weeks 24 and 52. The treatment effect was reduced in patients with high baseline serum intact parathyroid hormone (iPTH) compared with patients with low baseline serum iPTH. Compliant patients in the NAMR group had a more pronounced and sustained reduction in serum phosphate than non-compliant patients. NAMR treatment was associated with a significantly increased risk of thrombocytopenia, pruritus, anaemia, and diarrhoea. Herpes zoster occurred exclusively in patients randomized to NAMR.
CONCLUSIONS
NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Non-compliance may have contributed to reduced long-term efficacy. Several newly identified safety signals warrant further evaluation.
Identifiants
pubmed: 35751625
pii: 6617886
doi: 10.1093/ndt/gfac206
pmc: PMC10064978
doi:
Substances chimiques
Niacinamide
25X51I8RD4
Parathyroid Hormone
0
Phosphates
0
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
982-991Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
N Engl J Med. 2014 Jul 17;371(3):203-12
pubmed: 25014686
Perit Dial Int. 2009 Sep-Oct;29(5):562-7
pubmed: 19776051
NDT Plus. 2009 Jun;2(3):263-4
pubmed: 25984009
Pediatr Nephrol. 2016 Feb;31(2):289-96
pubmed: 26420678
Nefrologia. 2011;31(1):58-65
pubmed: 21270914
Clin Chim Acta. 2017 Nov;474:108-113
pubmed: 28903022
Dig Dis Sci. 1979 Sep;24(9):700-4
pubmed: 487925
Kidney Int Rep. 2020 Dec 19;6(3):594-604
pubmed: 33732974
Kidney Int. 2005 Dec;68(6):2911-2
pubmed: 16316377
Nephrol Dial Transplant. 2021 Jan 1;36(1):68-75
pubmed: 32879980
Drugs. 2018 Aug;78(12):1171-1186
pubmed: 30022383
PLoS One. 2015 Dec 04;10(12):e0144119
pubmed: 26636968
J Am Soc Nephrol. 2004 Aug;15(8):2208-18
pubmed: 15284307
N Engl J Med. 2014 Jul 17;371(3):288-90
pubmed: 25014706
Clin Infect Dis. 2016 Feb 15;62(4):462-7
pubmed: 26671505
Pharm Stat. 2016 Jul;15(4):315-23
pubmed: 27291933
Arch Intern Med. 2002 Jul 22;162(14):1568-76
pubmed: 12123399
Am J Kidney Dis. 2008 Sep;52(3):519-30
pubmed: 18514987
Nephrol Dial Transplant. 2005 Jul;20(7):1378-84
pubmed: 15870221
Medicine (Baltimore). 1972 Nov;51(6):451-64
pubmed: 4564417
BMC Nephrol. 2008 Jan 31;9:2
pubmed: 18237373
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59
pubmed: 30675420
BMC Infect Dis. 2018 May 3;18(1):203
pubmed: 29724175
J Am Soc Nephrol. 2009 Nov;20(11):2348-58
pubmed: 19729436
Am J Kidney Dis. 2012 Mar;59(3):428-33
pubmed: 22178678
Nephrol Dial Transplant. 2017 May 01;32(5):870-879
pubmed: 27190329
Hemodial Int. 2016 Jan;20(1):38-49
pubmed: 25975222
Nephrol Dial Transplant. 2011 Jun;26(6):1948-55
pubmed: 20466670
J Clin Lipidol. 2010 Mar-Apr;4(2):105-112.e1
pubmed: 21122637
Kidney Int. 2006 May;69(10):1914
pubmed: 16688193
Kidney Int. 2004 Mar;65(3):1099-104
pubmed: 14871431
Kidney Int. 2006 Aug;70(4):771-80
pubmed: 16820797
Circulation. 2012 Jan 3;125(1):150-8
pubmed: 22095827
Ann Transl Med. 2020 Apr;8(8):530
pubmed: 32411753
Indian J Nephrol. 2011 Oct;21(4):245-9
pubmed: 22022084
Clin J Am Soc Nephrol. 2008 Jul;3(4):1131-8
pubmed: 18385391
Ther Apher Dial. 2008 Feb;12(1):49-54
pubmed: 18257812
Diabetes Ther. 2018 Apr;9(2):545-550
pubmed: 29520743
J Nephrol. 2010 Sep-Oct;23(5):525-34
pubmed: 20119931
Heart. 2016 Feb;102(3):198-203
pubmed: 26370223
Nephrol Dial Transplant. 1999 May;14(5):1195-201
pubmed: 10344361
Int J Clin Pract. 2008 Dec;62(12):1959-70
pubmed: 19166443
Public Health. 2019 Feb;167:136-146
pubmed: 30660981
Kidney Int. 2020 Aug;98(2):343-354
pubmed: 32624180
Nephrol Dial Transplant. 2015 Sep;30(9):1542-51
pubmed: 25920921
Nephrol Dial Transplant. 2013 Jul;28(7):1922-35
pubmed: 23166310
Kidney Int. 2008 Jul;74(2):148-57
pubmed: 18449174